MariMed Statistics
Total Valuation
MariMed has a market cap or net worth of 48.13 million. The enterprise value is 141.94 million.
| Market Cap | 48.13M | 
| Enterprise Value | 141.94M | 
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
MariMed has 394.47 million shares outstanding. The number of shares has increased by 2.01% in one year.
| Current Share Class | 394.47M | 
| Shares Outstanding | 394.47M | 
| Shares Change (YoY) | +2.01% | 
| Shares Change (QoQ) | +1.92% | 
| Owned by Insiders (%) | 10.48% | 
| Owned by Institutions (%) | 0.37% | 
| Float | 353.14M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 0.31 | 
| PB Ratio | 0.66 | 
| P/TBV Ratio | 2.47 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | 24.31 | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.68, with an EV/FCF ratio of -63.96.
| EV / Earnings | -8.91 | 
| EV / Sales | 0.90 | 
| EV / EBITDA | 9.68 | 
| EV / EBIT | 142.94 | 
| EV / FCF | -63.96 | 
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 1.19.
| Current Ratio | 1.12 | 
| Quick Ratio | 0.27 | 
| Debt / Equity | 1.19 | 
| Debt / EBITDA | 5.94 | 
| Debt / FCF | -39.22 | 
| Interest Coverage | 0.14 | 
Financial Efficiency
Return on equity (ROE) is -19.76% and return on invested capital (ROIC) is 0.37%.
| Return on Equity (ROE) | -19.76% | 
| Return on Assets (ROA) | 0.30% | 
| Return on Invested Capital (ROIC) | 0.37% | 
| Return on Capital Employed (ROCE) | 0.65% | 
| Revenue Per Employee | 203,048 | 
| Profits Per Employee | -20,589 | 
| Employee Count | 832 | 
| Asset Turnover | 0.76 | 
| Inventory Turnover | 2.76 | 
Taxes
In the past 12 months, MariMed has paid 9.13 million in taxes.
| Income Tax | 9.13M | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has decreased by -21.54% in the last 52 weeks. The beta is 2.98, so MariMed's price volatility has been higher than the market average.
| Beta (5Y) | 2.98 | 
| 52-Week Price Change | -21.54% | 
| 50-Day Moving Average | 0.15 | 
| 200-Day Moving Average | 0.11 | 
| Relative Strength Index (RSI) | 39.42 | 
| Average Volume (20 Days) | 1,531,241 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | 0.05 | 
Income Statement
In the last 12 months, MariMed had revenue of 157.16 million and -15.94 million in losses. Loss per share was -0.04.
| Revenue | 157.16M | 
| Gross Profit | 60.66M | 
| Operating Income | 993,000 | 
| Pretax Income | -6.76M | 
| Net Income | -15.94M | 
| EBITDA | 12.56M | 
| EBIT | 993,000 | 
| Loss Per Share | -0.04 | 
Balance Sheet
The company has 6.14 million in cash and 87.03 million in debt, giving a net cash position of -80.89 million or -0.21 per share.
| Cash & Cash Equivalents | 6.14M | 
| Total Debt | 87.03M | 
| Net Cash | -80.89M | 
| Net Cash Per Share | -0.21 | 
| Equity (Book Value) | 73.17M | 
| Book Value Per Share | 0.15 | 
| Working Capital | 6.19M | 
Cash Flow
In the last 12 months, operating cash flow was 1.98 million and capital expenditures -4.20 million, giving a free cash flow of -2.22 million.
| Operating Cash Flow | 1.98M | 
| Capital Expenditures | -4.20M | 
| Free Cash Flow | -2.22M | 
| FCF Per Share | -0.01 | 
Margins
Gross margin is 38.60%, with operating and profit margins of 0.63% and -10.14%.
| Gross Margin | 38.60% | 
| Operating Margin | 0.63% | 
| Pretax Margin | -4.30% | 
| Profit Margin | -10.14% | 
| EBITDA Margin | 7.99% | 
| EBIT Margin | 0.63% | 
| FCF Margin | n/a | 
Dividends & Yields
MariMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -2.01% | 
| Shareholder Yield | n/a | 
| Earnings Yield | -33.11% | 
| FCF Yield | -4.61% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
MariMed has an Altman Z-Score of 0.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.24 | 
| Piotroski F-Score | 3 |